LeMaitre Vascular (LMAT) Form 144: Proposed Sale of 976 Shares

Rhea-AI Filing Summary

LeMaitre Vascular, Inc. (LMAT) filed a Form 144 proposing the sale of 976 common shares through Morgan Stanley Smith Barney LLC on 08/12/2025 on NASDAQ, with an aggregate market value of $90,553.28. The notice indicates 22,637,522 shares outstanding, so the position is a very small fraction of the company.

The 976 shares were acquired from the issuer as a mix of restricted stock and performance shares across five lots on dates in December 2024 and March 8, 2025 (198, 205, 201, 171, and 201 shares, which total 976). The filer reports no securities sold in the past three months and certifies they have no undisclosed material adverse information about the issuer.

Insights

Securities Analyst

TL;DR: Proposed sale is immaterial relative to outstanding shares; represents disposition of recently issued restricted and performance awards.

The filing shows a planned sale of 976 common shares via Morgan Stanley Smith Barney LLC with an aggregate market value of $90,553.28 against 22,637,522 shares outstanding. The securities were acquired from the issuer as restricted stock and performance shares in December 2024 and March 8, 2025, across five lots totaling 976 shares. There are no reported sales in the prior three months. Given the absolute size and described acquisition types, the transaction appears routine and unlikely to be material to share supply.

Corporate Governance Expert

TL;DR: Form 144 documents routine insider liquidity from issuer-originated awards and includes the standard representation about undisclosed material information.

The notice lists acquisitions exclusively from the issuer (restricted and performance awards) and discloses the broker, proposed sale date, and aggregate value. The filer affirms no known undisclosed material adverse information and reports nothing sold in the past three months. From a governance perspective, the disclosure follows required procedures for planned insider sales and provides clear acquisition provenance and broker routing.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	976	90553.28	22637522	08/12/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	12/11/2024	Restricted Stock	Issuer			198	12/11/2024	Not Applicable
Common	03/08/2025	Performance Shares	Issuer			205	03/08/2025	Not Applicable
Common	12/12/2024	Performance Shares	Issuer			201	12/12/2024	Not Applicable
Common	12/08/2024	Restricted Stock	Issuer			171	12/08/2024	Not Applicable
Common	12/12/2024	Restricted Stock	Issuer			201	12/12/2024	Not Applicable

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is LMAT selling according to the Form 144?

The filer proposes to sell 976 common shares of LeMaitre Vascular (LMAT) on 08/12/2025 on NASDAQ via Morgan Stanley Smith Barney LLC, with an aggregate market value of $90,553.28.

How were the 976 shares acquired?

The shares were acquired from the issuer as a mix of restricted stock and performance shares on dates in December 2024 and 03/08/2025 in five lots of 198, 205, 201, 171, and 201 shares (total 976).

Has the filer sold other LMAT securities in the past three months?

The filing states "Nothing to Report" for securities sold during the past three months.

Who is the broker handling the proposed sale?

The proposed sale is to be handled by Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza, 8th Floor, New York, NY.

How many LMAT shares are outstanding as reported in the filing?

The filing reports 22,637,522 shares outstanding.